HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine

Elmar A. Joura, Susanne K. Kjaer, Cosette M. Wheeler, Kristján Sigurdsson, Ole Erik Iversen, Mauricio Hernandez-Avila, Gonzalo Perez, Darron R. Brown, Laura A. Koutsky, Eng Hseon Tay, Patricia García, Kevin A. Ault, Suzanne M. Garland, Sepp Leodolter, Sven Eric Olsson, Grace W K Tang, Daron G. Ferris, Jorma Paavonen, Matti Lehtinen, Marc StebenXavier Bosch, Joakim Dillner, Robert J Kurman, Slawomir Majewski, Nubia Muñoz, Evan R. Myers, Luisa L. Villa, Frank J. Taddeo, Christine Roberts, Amha Tadesse, Janine Bryan, Lisa C. Lupinacci, Katherine E D Giacoletti, Shuang Lu, Scott Vuocolo, Teresa M. Hesley, Richard M. Haupt, Eliav Barr

Research output: Contribution to journalArticle


The efficacy of the quadrivalent Human Papillomavirus (HPV) vaccine is thought to be mediated by humoral immunity. We evaluated the correlation between quadrivalent HPV vaccine-induced serum anti-HPV responses and efficacy. 17,622 women were vaccinated at day 1, and months 2 and 6. At day 1 and at 6-12 months intervals for up to 48 months, subjects underwent Papanicolaou and genital HPV testing. No immune correlate of protection could be found due to low number of cases. Although 40% of vaccine subjects were anti-HPV 18 seronegative at end-of-study, efficacy against HPV 18-related disease remained high (98.4%; 95% CI: 90.5-100.0) despite high attack rates in the placebo group. These results suggest vaccine-induced protection via immune memory, or lower than detectable HPV 18 antibody titers.

Original languageEnglish (US)
Pages (from-to)6844-6851
Number of pages8
Issue number52
StatePublished - Dec 9 2008



  • Human Papillomavirus
  • Humoral immunity
  • Immune memory

ASJC Scopus subject areas

  • Immunology and Microbiology(all)
  • Infectious Diseases
  • Public Health, Environmental and Occupational Health
  • veterinary(all)
  • Molecular Medicine

Cite this

Joura, E. A., Kjaer, S. K., Wheeler, C. M., Sigurdsson, K., Iversen, O. E., Hernandez-Avila, M., Perez, G., Brown, D. R., Koutsky, L. A., Tay, E. H., García, P., Ault, K. A., Garland, S. M., Leodolter, S., Olsson, S. E., Tang, G. W. K., Ferris, D. G., Paavonen, J., Lehtinen, M., ... Barr, E. (2008). HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine, 26(52), 6844-6851. https://doi.org/10.1016/j.vaccine.2008.09.073